Cargando…

Proportional Feedback Control of Energy Intake during Obesity Pharmacotherapy

OBJECTIVE: Obesity pharmacotherapies result in an exponential time course for energy intake whereby large early decreases dissipate over time. This pattern of declining drug efficacy to decrease energy intake results in a weight loss plateau within approximately one year. We aimed to elucidate the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hall, Kevin D., Sanghvi, Arjun, Göbel, Britta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757521/ https://www.ncbi.nlm.nih.gov/pubmed/29071809 http://dx.doi.org/10.1002/oby.21978

Ejemplares similares

Quantifying Energy Intake Changes during Obesity Pharmacotherapy
por: Göbel, Britta, et al.
Publicado: (2014)

Pharmacotherapy for Obesity
por: Joo, Jong Kil, et al.
Publicado: (2014)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Obesity pharmacotherapy: current status
por: Kumar, Parveen, et al.
Publicado: (2015)

Obesity Treatment – Is Pharmacotherapy the Answer?
por: Rangbulla, Aditya Kumar
Publicado: (2020)

Pharmacology and Pharmacotherapy
por: Berger, Dietmar P., et al.
Publicado: (2008)

Cost-Effectiveness of Pharmacotherapy to Reduce Obesity
por: Veerman, J. Lennert, et al.
Publicado: (2011)

Total Energy Intake May Be More Associated with Glycemic Control Compared to Each Proportion of Macronutrients in the Korean Diabetic Population
por: Kang, Hye Mi, et al.
Publicado: (2012)

Obesity Pharmacotherapy: Current Perspectives and Future Directions
por: Misra, Monika
Publicado: (2013)

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
por: Srivastava, Gitanjali, et al.
Publicado: (2019)

Pharmacotherapies for Obesity: Past, Current, and Future Therapies
por: Ioannides-Demos, Lisa L., et al.
Publicado: (2011)

Obesity Pharmacotherapy in Patients With Type 2 Diabetes
por: Kahan, Scott, et al.
Publicado: (2017)

Current Long-Term Pharmacotherapies for the Management of Obesity
por: Kim, Bo-Yeon, et al.
Publicado: (2020)

GLP-1 physiology informs the pharmacotherapy of obesity
por: Drucker, Daniel J.
Publicado: (2021)

Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents
por: Lim, Francesca, et al.
Publicado: (2023)

Low-level proportional counter for tritium
por: Charalambous, S, et al.
Publicado: (1963)

The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in‐person encounters
por: Griebeler, Marcio L., et al.
Publicado: (2022)

A biomolecular proportional integral controller based on feedback regulations of protein level and activity
por: Mairet, Francis
Publicado: (2018)

Interception by two predatory fly species is explained by a proportional navigation feedback controller
por: Fabian, Samuel T., et al.
Publicado: (2018)

The cost‐effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity
por: Lee, Minyi, et al.
Publicado: (2019)

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
por: Tan, Qiming, et al.
Publicado: (2022)

The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA
por: Baum, Charles, et al.
Publicado: (2015)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Pharmacotherapy for chronic obesity management: a look into the future
por: Abdel-Malek, Mariana, et al.
Publicado: (2023)

A genetic mammalian proportional–integral feedback control circuit for robust and precise gene regulation
por: Frei, Timothy, et al.
Publicado: (2022)

Objective versus Self-Reported Energy Intake Changes During Low-Carbohydrate and Low-Fat Diets
por: Guo, Juen, et al.
Publicado: (2019)

A hierarchy of biomolecular proportional-integral-derivative feedback controllers for robust perfect adaptation and dynamic performance
por: Filo, Maurice, et al.
Publicado: (2022)

Energy Expenditure in Pregnant Women with Obesity Does Not Support Energy Intake Recommendations
por: Most, Jasper, et al.
Publicado: (2018)

The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake
por: Kim, Junga, et al.
Publicado: (2013)

Meal patterns associated with energy intake in people with obesity
por: Horn, Cathrine, et al.
Publicado: (2022)

Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
por: Merlino, Dante J., et al.
Publicado: (2014)

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
por: Anandhakrishnan, Ananthi, et al.
Publicado: (2016)

LEAP2: Next game-changer of pharmacotherapy for overweight and obesity?
por: Liu, Dan, et al.
Publicado: (2022)

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
por: Chakhtoura, Marlene, et al.
Publicado: (2023)

Effects of Pharmacotherapy for the Treatment of Obesity in an Urban, Safety-Net Population
por: Kim, Eric K, et al.
Publicado: (2023)

The characterisation of overweight and obese women who are under reporting energy intake during pregnancy
por: Moran, L. J., et al.
Publicado: (2018)

Pharmacotherapy during Pregnancy, Childbirth, and Lactation
por: Allegaert, Karel
Publicado: (2022)

Efferent feedback controls bilateral auditory spontaneous activity
por: Wang, Yixiang, et al.
Publicado: (2021)

Obtaining a Proportional Allocation by Deleting Items
por: Dorn, Britta, et al.
Publicado: (2021)

Discordance between gut-derived appetite hormones and energy intake in humans
por: Hengist, Aaron, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qdhkp60s8p79lgq1ofnuj0qdr2